Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Study of Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women

Trial Profile

Pilot Study of Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/tenofovir-disoproxil-fumarate (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms TRANSViiV
  • Most Recent Events

    • 01 Aug 2018 Planned End Date changed from 1 Dec 2017 to 1 Jul 2019.
    • 01 Aug 2018 Planned primary completion date changed from 1 Oct 2017 to 1 May 2019.
    • 01 Aug 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top